Home
LDNNow on social media
Campaign News
Studies and Research
Dr Zagon and Dr McLaughlin’s Work
Funding
Experimental Biology Meeting LDN
Experimental Biology Meeting OGF
LDN Side Effects
Articles and Press
Petitions
LDN and OGF Pharmacies
LDNNow Blog
Guestbook
Contact
   
 


Leslie A Hammer



“Opioid growth factor (OGF) reversesthe progression of clinical disease in established relapse-remittingexperimental autoimmune encephalomyelitis - a model for multiple sclerosis”

Relapse-remitting multiple sclerosis (RR-MS) is a chronic disorder involving inflammatory attacks on the Central Nervous System. RR-MS affects about 350,000 people in the U.S. significantly reducing their quality of life, and eventually may results in paralysis.

At the Experimental Biology conference held in San Diego recently (April 2014), Leslie A. Hammer, a graduate student in Anatomy, presented a poster and talk (titled above) about her pre-clinical work conducted in the laboratories of Drs Zagon and McLaughlin at the Department of Neural and Behavioral Sciences, Penn State University College of Medicine, Hershey, Pennsylvania, USA.

OGF, chemically termed [Met5]-enkephalin, was administered daily to female mice with established relapse-remitting experimental autoimmune encephalomyelitis (RR-EAE).  Mice were immunized with PLP139-151 in complete Freund’s adjuvant, and beginning 2 days after initial behavioral signs received daily injections of OGF (10 mg/kg) or sterile saline.  

Within 9 days of treatment with OGF the mice had markedly reduced mean behavior scores relative to controls; the sum of the behavior scores was 140.1±14.4 for the RR-EAE+Saline group in comparison to 72.2±11.5 for the RR-EAE+OGF group.

Disease severity scores were 16.3± 5 for RR-EAE+Saline in comparison to 3.6±1.7 for OGF treated mice.

No saline-treated mouse had a complete remission, whereas 83% of OGF mice had complete remissions (behavioral score ≤ 0.5); the total length of time in complete remission was 9.1±3.4 days for the RR-EAE+OGF animals over the course of the 40-day experimental period.

In summary, treatment with OGF initiated at the time of discernible disease reduced the intensity of the initial flair, reversed the progression of RR-EAE, and resulted in complete clinical remission, supporting its use as a novel therapy for the treatment of MS.

By participating at this event, Leslie was able to raise the profile of LDN and OGF into the scientific/medical community which attracted some media attention.  We are pleased that donations received from LDN users facilitated the exposure of such important work allowing it to gain traction.